Depo-provera and Vaginal discharge - a phase IV clinical study of FDA data

Summary:

Vaginal discharge is reported as a side effect among people who take Depo-provera (medroxyprogesterone acetate), especially for people who are 20-29 old, have been taking the drug for < 1 month also take Mirena, and have Heavy or prolong menstrual bleeding.

The phase IV clinical study analyzes which people have Vaginal discharge when taking Depo-provera. It is created by eHealthMe based on reports of 15,804 people who have side effects when taking Depo-provera from the FDA, and is updated regularly.

What is Depo-provera?

Depo-provera has active ingredients of medroxyprogesterone acetate. It is often used in birth control. eHealthMe is studying from 17,093 Depo-provera users. Check the latest studies of Depo-provera.

What is Vaginal discharge?

Vaginal discharge is found to be associated with 640 drugs and 1,202 conditions by eHealthMe. Check the latest studies of Vaginal discharge.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

15,804 people reported to have side effects when taking Depo-provera.
Among them, 72 people (0.46%) have Vaginal discharge.

Could Depo-provera cause Vaginal discharge?

Among these 72 people:

How long have people been on Depo-provera when they have Vaginal discharge? *

What is the age of people who have Vaginal discharge when taking Depo-provera? *

What are other drugs people take besides Depo-provera? *

What are other side effects people have besides Vaginal discharge? *

Abdominal Pain: 20 people, 27.78%
Headache (pain in head): 19 people, 26.39%
Nausea (feeling of having an urge to vomit): 17 people, 23.61%
Depression: 16 people, 22.22%
Vaginal Bleeding: 16 people, 22.22%
Weight Increased: 15 people, 20.83%
Fatigue (feeling of tiredness): 15 people, 20.83%
Back Pain: 15 people, 20.83%
Heavy Or Prolong Menstrual Bleeding: 15 people, 20.83%
Dysmenorrhea (painful menstruation): 13 people, 18.06%

What are the existing conditions these people have? *

Heavy Or Prolong Menstrual Bleeding: 6 people, 8.33%
Bipolar Disorder (mood disorder): 5 people, 6.94%
Psychotic Disorder: 5 people, 6.94%
Depression: 4 people, 5.56%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 4 people, 5.56%
Uterine Leiomyoma (uterine benign tumour derived from smooth muscle): 3 people, 4.17%
Sleep Disorder: 3 people, 4.17%
Insomnia (sleeplessness): 3 people, 4.17%
Impaired Gastric Emptying: 2 people, 2.78%
Menstrual Discomfort: 2 people, 2.78%

* Approximation only. Some reports may have incomplete information.

Do you take Depo-provera and have Vaginal discharge?

- Check whether Vaginal discharge is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Depo-provera:

Depo-provera (17,093 reports)

Browse all side effects of Depo-provera:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Vaginal discharge:

Vaginal discharge (640 drugs)

Browse all the conditions that are associated with Vaginal discharge:

Vaginal discharge (1,202 conditions)

Related publications that referenced our studies

Bahall M, Reyes AJ, Ramcharan K, Hosein N, Seegobin K, Bahall K, Sharma H, Dhansingh S, Mahabir A, "Neuro-ophthalmological manifestations after intramuscular medroxyprogesterone: a forme fruste of idiopathic intracranial hypertension?", Neurology international, 2016 Sep .
Bahall M, Reyes AJ, Ramcharan K, Hosein N, Seegobin K, Bahall K, Sharma H, Dhansingh S, Mahabir A, "Neuro-ophthalmological manifestations after intramuscular medroxyprogesterone: a forme fruste of idiopathic intracranial hypertension?", Neurology international, 2016 Sep .

How the study uses the data?

The study uses data from the FDA. It is based on medroxyprogesterone acetate (the active ingredients of Depo-provera) and Depo-provera (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.